Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression.
Hypertension
Meta-analysis
Polycystic ovary syndrome
Relative risk
Journal
Reproductive biology and endocrinology : RB&E
ISSN: 1477-7827
Titre abrégé: Reprod Biol Endocrinol
Pays: England
ID NLM: 101153627
Informations de publication
Date de publication:
17 Mar 2020
17 Mar 2020
Historique:
received:
26
10
2019
accepted:
24
02
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
2
2
2021
Statut:
epublish
Résumé
A limited number of publications have assessed the prevalence of hypertension (HTN) in polycystic ovary syndrome (PCOS) patients with inconclusive results. Since in general populations the occurrence of hypertension is related to age per se, we investigated the prevalence (P) / relative risk (RR) of HTN in pooled patients with PCOS, vs control population among reproductive age women with PCOS, compared to menopause/aging patients. PubMed, Scopus, ScienceDirect, web of science, and Google scholar were systematically searched for retrieving observational studies published from inception to April 2019 investigating the HTN in patients with PCOS. The primary outcome of interest was pooled P and RR of HTN in reproductive and menopausal/aging women with PCOS compared to control population. The pooled prevalence of HTN in reproductive and menopausal/aging women with PCOS was higher than in the control population [(Pooled P: 0.15, 95% CI: 0.12-0.18 vs. Pooled P: 0.09, 95% CI: 0.08-0.10) and (Pooled P: 0.49, 95% CI: 0.28-0.70 vs. Pooled P: 0.40, 95% CI: 0.22-0.57), respectively]. Compared to the control population, pooled relative risk (RR) of HTN patients was increased only in reproductive age PCOS (1.70-fold, 95% CI: 1.43-2.07) but not in menopausal/aging patients who had PCOS during their reproductive years. The same results were obtained for subgroups of population-based studies. Meta-regression analysis of population-based studies showed that the RR of HTN in reproductive age PCOS patients was 1.76-fold than menopausal/aging PCOS patients (P = 0.262). This meta-analysis confirms a greater risk of HTN in PCOS patients but demonstrates that this risk is increased only in reproductive age women with PCOS, indicating that after menopause, having a history of PCOS may not be as an important predisposing factor for developing HTN.
Sections du résumé
BACKGROUND
BACKGROUND
A limited number of publications have assessed the prevalence of hypertension (HTN) in polycystic ovary syndrome (PCOS) patients with inconclusive results. Since in general populations the occurrence of hypertension is related to age per se, we investigated the prevalence (P) / relative risk (RR) of HTN in pooled patients with PCOS, vs control population among reproductive age women with PCOS, compared to menopause/aging patients.
METHODS
METHODS
PubMed, Scopus, ScienceDirect, web of science, and Google scholar were systematically searched for retrieving observational studies published from inception to April 2019 investigating the HTN in patients with PCOS. The primary outcome of interest was pooled P and RR of HTN in reproductive and menopausal/aging women with PCOS compared to control population.
RESULTS
RESULTS
The pooled prevalence of HTN in reproductive and menopausal/aging women with PCOS was higher than in the control population [(Pooled P: 0.15, 95% CI: 0.12-0.18 vs. Pooled P: 0.09, 95% CI: 0.08-0.10) and (Pooled P: 0.49, 95% CI: 0.28-0.70 vs. Pooled P: 0.40, 95% CI: 0.22-0.57), respectively]. Compared to the control population, pooled relative risk (RR) of HTN patients was increased only in reproductive age PCOS (1.70-fold, 95% CI: 1.43-2.07) but not in menopausal/aging patients who had PCOS during their reproductive years. The same results were obtained for subgroups of population-based studies. Meta-regression analysis of population-based studies showed that the RR of HTN in reproductive age PCOS patients was 1.76-fold than menopausal/aging PCOS patients (P = 0.262).
CONCLUSION
CONCLUSIONS
This meta-analysis confirms a greater risk of HTN in PCOS patients but demonstrates that this risk is increased only in reproductive age women with PCOS, indicating that after menopause, having a history of PCOS may not be as an important predisposing factor for developing HTN.
Identifiants
pubmed: 32183820
doi: 10.1186/s12958-020-00576-1
pii: 10.1186/s12958-020-00576-1
pmc: PMC7076940
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
23Références
Eur J Obstet Gynecol Reprod Biol. 2014 Feb;173:66-70
pubmed: 24368020
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Clin Endocrinol Metab. 1999 Jun;84(6):1897-9
pubmed: 10372683
J Clin Endocrinol Metab. 2006 Apr;91(4):1357-63
pubmed: 16434451
Womens Health (Lond). 2008 Nov;4(6):583-94
pubmed: 19072461
Gynecol Endocrinol. 2007 Dec;23(12):704-9
pubmed: 18075845
Oncotarget. 2018 Jan 4;9(9):8756-8764
pubmed: 29492235
J Clin Endocrinol Metab. 2005 Oct;90(10):5711-6
pubmed: 16046590
Hum Reprod. 2003 Jul;18(7):1438-41
pubmed: 12832369
Nat Rev Endocrinol. 2018 May;14(5):270-284
pubmed: 29569621
Acta Obstet Gynecol Scand. 1992 Dec;71(8):599-604
pubmed: 1336918
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Neth J Med. 2012 Mar;70(2):74-80
pubmed: 22418753
Gynecol Endocrinol. 2020 Jan;36(1):12-23
pubmed: 31385729
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Obstet Gynecol Int. 2012;2012:306347
pubmed: 22262974
Am J Med. 2013 Jul;126(7):640.e1-7
pubmed: 23688663
PLoS One. 2015 Sep 11;10(9):e0137609
pubmed: 26360602
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
Hum Reprod. 2003 May;18(5):980-4
pubmed: 12721172
CMAJ. 2013 Feb 5;185(2):E115-20
pubmed: 23209115
J Clin Endocrinol Metab. 2011 Dec;96(12):3794-803
pubmed: 21956415
Clin Endocrinol (Oxf). 2016 Jul;85(1):92-9
pubmed: 26608823
Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2688-94
pubmed: 25359859
Minerva Ginecol. 2004 Feb;56(1):1-6
pubmed: 14973405
J Clin Endocrinol Metab. 2003 Jun;88(6):2562-8
pubmed: 12788855
J Clin Endocrinol Metab. 1992 Aug;75(2):508-13
pubmed: 1639952
Ann Intern Med. 1987 Aug;107(2):224-33
pubmed: 3300460
Hum Reprod. 1996 Jan;11(1):23-8
pubmed: 8671152
Hum Reprod. 2007 Dec;22(12):3197-203
pubmed: 17933750
Arch Public Health. 2014 Nov 10;72(1):39
pubmed: 25810908
J Clin Endocrinol Metab. 2006 Nov;91(11):4237-45
pubmed: 16940456
J Womens Health (Larchmt). 2016 Sep;25(9):875-81
pubmed: 27267867
Fertil Steril. 2014 Feb;101(2):530-5
pubmed: 24382375
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
J Investig Med. 2014 Aug;62(6):868-74
pubmed: 24844662
Nat Rev Endocrinol. 2011 Apr;7(4):219-31
pubmed: 21263450
Reprod Biol Endocrinol. 2014 Sep 16;12:89
pubmed: 25224635
J Clin Endocrinol Metab. 2004 Nov;89(11):5592-6
pubmed: 15531516
J Clin Epidemiol. 1998 May;51(5):415-22
pubmed: 9619969
BJOG. 2005 Oct;112(10):1427-30
pubmed: 16167950
Fertil Steril. 2019 Mar;111(3):579-587.e1
pubmed: 30827526
J Clin Endocrinol Metab. 2006 Mar;91(3):781-5
pubmed: 16418211
J Clin Endocrinol Metab. 2015 Mar;100(3):911-9
pubmed: 25532045
Hum Reprod. 2013 Sep;28(9):2562-9
pubmed: 23814096
Fertil Steril. 2018 Dec;110(7):1377-1386
pubmed: 30503137
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Am J Hypertens. 2015 Jul;28(7):847-51
pubmed: 25542625
Reprod Biol Endocrinol. 2011 Mar 25;9:39
pubmed: 21435276
Eur J Endocrinol. 2015 May;172(5):627-38
pubmed: 25656495
J Clin Endocrinol Metab. 2007 Dec;92(12):4609-14
pubmed: 17848406
Hum Reprod. 2013 Aug;28(8):2245-52
pubmed: 23595974
Hum Reprod. 2000 Apr;15(4):785-9
pubmed: 10739820
Fertil Steril. 2014 Nov;102(5):1444-1451.e3
pubmed: 25239303
Thromb Res. 2015 Dec;136(6):1165-8
pubmed: 26489726
Clin Endocrinol (Oxf). 2011 Jan;74(1):89-96
pubmed: 21044112
Climacteric. 2009;12 Suppl 1:22-5
pubmed: 19811236
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1622-1630
pubmed: 29408955
Fertil Steril. 2017 Dec;108(6):1078-1084
pubmed: 29202960
Fertil Steril. 2017 Dec;108(6):959-960
pubmed: 29202973
Clin Endocrinol (Oxf). 2000 May;52(5):595-600
pubmed: 10792339